The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2006AAV-Based Approach for Regulatable and Cell Type-Specific Gene Therapy in PD: Restoring Excitability to an Intrinsically Silenced Subpopulation of GP Neurons
Abnormally synchronized activity within the basal ganglia, specifically between the external globus pallidus (GPe) and subthalamic nucleus (STN), is a hallmark of altered network activity in Parkinson...
-
Community Fast Track, 2006Intravenous GDNF Gene Therapy of Experimental Parkinson's Disease
Parkinson's disease is caused by the loss of cells in the brain that produce a chemical called dopamine, which is also called a monoamine. The loss of these cells has been delayed in pre-clinical...
-
Community Fast Track, 2006Molecular Regulators of Dopamine Synthesis
The death of certain brain cells known as nigrostriatal neurons, which produce the neurochemical known as dopamine, ultimately causes movement dysfunction and reduced quality of life for individuals...
-
Community Fast Track, 2006Establishing a role of Nurr1 in adult DA neurons by conditional gene ablation in the adult substantia nigra
We will investigate the function of the protein Nurr1 in the adult mouse brain. Nurr1 belongs to the family of steroid hormone receptors but lacks an identified ligand. We have previously shown that...
-
Community Fast Track, 2006Engrailed as a Potential Therapeutic Target in Parkinson's Disease
Parkinson’s disease is associated with the preferential loss of a population of dopaminergic neurons in the substantia nigra, a specific structure of the midbrain. It was shown very recently that...
-
Community Fast Track, 2006Study of the Role of Phosphorylation at Ser 129 in Alpha-synuclein Induced Dopaminergic Neurodegeneration in a Rodent Model of Parkinson's Disease
The involvement of alpha-synuclein in Parkinson's disease neurodegeneration is now widely accepted. However, factors and events contributing to the alpha-synuclein toxicity are still being...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.